9月19日 由省工商联主办的 2025云南省民营企业100强发布会 在昆明举行 会上发布了 "民营企业100强" "制造业20强""服务业20强" "创新能力20强""吸纳就业20强" 5个榜单 据了解 本次发布首次采用了 | 排名 企业名称 | 所属州市 所属行业 | 营业收入 | | --- | --- | --- | | | | (万元) | | 1 云南玉溪玉昆钢铁集团有限 | C31 黑色金属冶炼和 玉溪市 man of the Tilli | 2866840 | | | 云南曲靖呈铜钢铁(集团) | | 东处 川上 Y C31 黑色金属治短 | | | --- | --- | --- | --- | --- | | 2 | 有限公司 | 曲靖市 | 乐3正力工业 | 2608652 | | ਤੇ | 云南宏泰新型材料有限公司 | 文山壮族 苗族自治州 | C32 有色金属冶炼和 乐3正力0丁 | 2399073 | | | | | C39 计算机、通信和 | | | 4 | 品明周讯学 卓限公司 | 是明市 | 其他电子设备制造业 | 2380377 | | 5 | 云南玉溪山福钢铁(集团)有 | ...

证券日报网讯 9月18日晚间，一心堂发布公告称，2025年中期权益分派方案为向全体股东每10股派发现 金红利2.00元（含税）。股权登记日为2025年9月24日，除权除息日为2025年9月25日。 （编辑 姚尧） ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-084 号 特别提示： 根据《公司法》《上市公司股份回购规则》等相关规定，一心堂药业集团股份有限公司（以 下简称"公司"或"本公司"）通过股份回购专用证券账户持有的本公司股份11,475,900股不 享有参与权益分派的权利。本次权益分派以2025年半年度权益分派方案实施时股权登记日的总 股本扣除公司回购专用账户股份数为基数，向全体股东每10股派发现金红利2元(含税)，不送红 股，不以资本公积金转增股本，本次现金分红总额为114,825,645.00（含税)。 公司2025年中期权益分派方案已获2025年9月16日召开的2025年度第二次临时股东会审议 通过，现将权益分派事宜公告如下： 一、股东会审议通过的权益分派方案情况 1、公司 2025 年度第二次临时股东会审议通过的利润分配方案为：公司决定以 2025 年半年 度权益分派方案实施时股权登记日的总股本扣除公司回购专用账户股份数为基数，向全体股东 每 10 股派发现金红利 2 元(含税)，不送红股，不以资本公积金转增股本，本次现金分红总额为 114,825,645.00（含税) ...

中国北京市朝阳区建国路 77 号华贸中心 3 号写字楼 34 层 邮政编码 100025 电话: (86-10) 5809-1000 传真: (86-10) 5809-1100 北京市竞天公诚律师事务所 关于一心堂药业集团股份有限公司 致：一心堂药业集团股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）以及中国证券监 督管理委员会颁布的《上市公司股东会规则（2025年修订）》（以下简称"《股 东会规则》"）的规定，北京市竞天公诚律师事务所（以下简称"本所"）指派律 师对一心堂药业集团股份有限公司（以下简称"公司"）2025年度第二次临时股东 会（以下简称"本次股东会"）进行现场见证，并就本次股东会的有关事宜出具本 法律意见书。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法（2023）》和《律师事务所证券法律业务执业规则（试行）》等规 定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定职责， 遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见书所 认定的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记 载、误导性 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-083 号 一心堂药业集团股份有限公司 2025 年度第二次临时股东会暨中小投资者表决结果公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会没有增加、否决或变更提案。 2.本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 （一）会议召开情况 1.召开时间： （1）现场会议时间：2025 年 9 月 16 日（星期二）下午 14 点。 （2）网络投票时间：2025 年 9 月 16 日。其中，通过深圳证券交易所交易系统进行网络 投票的具体时间为 2025 年 9 月 16 日 9:15—9:25，9:30—11:30 和 13:00—15:00；通过深圳证 券交易所互联网投票系统进行网络投票的具体时间为 2025 年 9 月 16 日上午 9:15 至下午 15:00 的任意时间。 2.召开地点：一心堂药业集团股份有限公司会议室 股，占公司有表决权股份总数 574,128,225 股（注:截至本次股东会股权登记日，公司总股本 为 585,6 ...

Core Viewpoint - The article discusses the sudden decline of the pharmacy industry in China, highlighting the rapid closure of stores and the challenges faced by pharmacy owners and employees due to various market and regulatory changes [7][13][31]. Group 1: Industry Overview - In the past year, approximately 39,000 pharmacies closed nationwide, with a closure rate of 5.7%, and predictions suggest an additional 60,000 to 100,000 closures this year [13]. - The pharmacy industry, once considered a "golden track" for investment, has seen major players like Guoda Pharmacy and Shandong's Shuyupingmin Pharmacy struggling, with significant store closures and stock sell-offs by shareholders [16][31]. Group 2: Factors Contributing to Decline - The decline is attributed to three main factors: competition from community hospitals, the rise of online pharmacies, and tightening regulations on medical insurance reimbursements [34][41][49]. - Community hospitals have become popular among younger consumers, leading to a loss of clientele for pharmacies, particularly in the chronic disease segment [36][40]. - Online platforms have disrupted traditional pharmacy sales, offering lower prices and convenience, which has eroded the competitive edge of brick-and-mortar pharmacies [42][46]. Group 3: Financial Impact - Many listed pharmacy chains are experiencing significant profit declines, with net profit reductions starting at 60%, and some companies like Shuyupingmin facing potential losses of up to 220 million yuan [31][50]. - The shift in the market has forced many pharmacy owners to seek alternative employment, with some transitioning to factory work or food delivery services [22][23]. Group 4: Adaptation Strategies - Pharmacies are attempting to adapt by diversifying their offerings, such as incorporating health seminars and free health check-ups to build community ties and enhance customer loyalty [58][67]. - The future of the pharmacy industry is expected to focus on professional services and operational efficiency rather than mere expansion, with some pharmacies exploring AI-assisted consultations to improve service delivery [70].

Core Viewpoint - YXTT's stock price has shown fluctuations in recent trading sessions, with a year-to-date increase of 16.53% but a recent decline of 1.00% over the last five trading days [2] Group 1: Stock Performance - As of September 11, YXTT's stock price was 14.83 CNY per share, with a market capitalization of 8.685 billion CNY [1] - The stock has experienced a 2.05% decline during the trading session on September 11, with a trading volume of 41.0343 million CNY and a turnover rate of 0.69% [1] - Year-to-date, YXTT has appeared on the "Dragon and Tiger List" twice, with the most recent appearance on May 23, where it recorded a net buy of -4.0951 million CNY [2] Group 2: Financial Performance - For the first half of 2025, YXTT reported a revenue of 8.914 billion CNY, a year-on-year decrease of 4.20%, and a net profit attributable to shareholders of 250 million CNY, down 11.44% year-on-year [2] - Cumulative cash dividends since YXTT's A-share listing amount to 1.908 billion CNY, with 649 million CNY distributed over the past three years [3] Group 3: Shareholder Structure - As of June 30, 2025, YXTT had 33,900 shareholders, a decrease of 5.42% from the previous period, with an average of 11,712 circulating shares per shareholder, an increase of 5.73% [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 18.5744 million shares, a decrease of 21.1993 million shares from the previous period [3] - New entrants among the top ten shareholders include several funds, such as Guangfa Technology Innovation Mixed Fund and Invesco Great Wall Growth Star Stock A [3]

Core Points - YXTT announced the election of Guo Chunli as the employee representative director of the sixth board of directors, effective from the date of the employee representative assembly's approval until the end of the board's term [1] Group 1 - The employee representative assembly was held on September 5, 2025 [1] - Guo Chunli was democratically elected by the attending employee representatives [1]

一心为民 全心服务 董事会 2025 年 9 月 5 日 第 1 页 共 2 页 股票代码：002727 股票简称：一心堂 公告编号：2025-082 号 一心堂药业集团股份有限公司 关于选举第六届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》《上市公司章程指引》《深圳证券交易所上市公司自律监 管指引第1号——主板上市公司规范运作》等法律、法规、规范性文件及《公司章程》的有关规 定，公司于2025年9月5日召开了职工代表大会，经与会职工代表民主选举，选举郭春丽女士（简 历详见附件）为第六届董事会职工代表董事，任期自公司职工代表大会选举通过之日起至公司 第六届董事会任期届满之日止。 本次选举完成后，郭春丽女士由原公司第六届董事会非职工代表董事变更为公司第六届董 事会职工代表董事，公司第六届董事会构成人员不变，董事会中兼任公司高级管理人员以及由 职工代表担任的董事人数总计未超过公司董事总数的二分之一，符合有关法律法规、规范性文 件及《公司章程》的规定。 特此公告。 一心堂药业集团股份有限公司 一心为民 全心服 ...

Core Insights - The retail pharmacy industry is experiencing a significant transformation, with a shift from expansion to rapid contraction due to competition from online platforms like JD.com and Meituan [1][6][11] Industry Overview - In the first half of 2025, the retail pharmacy sector faced severe challenges, with four out of seven major chain pharmacies reporting revenue declines, while three maintained growth [1][3] - The overall growth of the retail pharmacy industry is slowing down, with a notable divergence in profitability among companies [4][5] Financial Performance - Major players include: - Dazhonglin: Revenue of 135.22 billion yuan, up 1.3%, net profit of 7.98 billion yuan, up 21.4% [3][4] - Yifeng Pharmacy: Revenue of 117.22 billion yuan, down 0.35%, net profit of 8.8 billion yuan, up 10.32% [3][4] - Laobaixing: Revenue of 107.74 billion yuan, down 1.51%, net profit of 3.98 billion yuan, down 20.86% [3][4] - Yixin Hall: Revenue of 89.14 billion yuan, down 4.20%, net profit of 2.50 billion yuan, down 11.44% [3][4] - Huaren Health: Revenue of 25.04 billion yuan, up 15.52%, net profit of 1.04 billion yuan, up 42.17% [3][4] Store Expansion and Market Dynamics - The industry is witnessing a trend of store closures, with major chains like Laobaixing, Yifeng, and Yixin Hall reducing their store counts significantly [6][11] - Approximately 3,000 pharmacies closed in the first quarter of 2025, indicating a significant market reshuffle [6] Competitive Pressures - The rise of online platforms has intensified competition, leading to price disparities in non-prescription drugs and health products, which has negatively impacted the average transaction value and gross margins of physical pharmacies [6][7] Regulatory and Cost Challenges - Recent policy changes, including healthcare reforms and procurement expansions, have severely impacted traditional profit models of pharmacies [7] - Rising operational costs, including rent and labor, along with expenses related to digital transformation, are increasing the financial burden on retail pharmacies [7] Strategic Responses - In response to online competition, pharmacies are diversifying their business models beyond just selling medications, venturing into health management and beauty products [9][10] - Initiatives include providing personalized medication guidance, health management services, and expanding into non-pharmaceutical product sales [10] Future Outlook - The retail pharmacy industry is expected to face more challenges and opportunities in the second half of 2025, with ongoing impacts from procurement policies and healthcare reforms [11]